# US 2025/0367303 A1 · Polypeptide that passes through blood-brain barrier, and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0367303 A1
- Document ID: US20250367303A1
- Status: Published application
- Kind: A1
- Application number: 18/861,693
- Filed: 2023-05-16
- Published: 2025-12-04
- Earliest claimed: 2022-05-16
- Assignees: Korea University Research and Business Foundation; Medi&Gene Inc.
- Applicants: Korea University Research and Business Foundation; Medi & Gene Inc.
- Inventors: Min-Jeong SHIN; In Hyeok CHUNG; Chan PARK
- Web page: https://patentgrep.com/patent/US20250367303A1

## CPC

- A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65)
- A61P 25/00: Drugs for disorders of the nervous system
- A61K 49/0056: {Peptides, proteins, polyamino acids}
- C07K 7/06: having 5 to 11 amino acids
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- C07K 14/00: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K 14/245: Escherichia (G)
- C12N 15/70: Vectors or expression systems specially adapted for E. coli
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/10: containing a tag for extracellular membrane crossing, e.g. TAT or VP22
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to a polypeptide that passes through a blood-brain barrier or cerebrovascular barrier and a use of the polypeptide for material delivery, and the polypeptide can deliver a material that naturally cannot pass through the blood-brain barrier such as protein into brain tissue.

## Claims

### Claim 1

A blood-brain barrier permeable peptide comprising an amino acid sequence of SEQ ID NO: 3 or SEQ ID NO: 5.

### Claim 2 (depends on 1)

The blood-brain barrier permeable peptide according to claim 1, wherein the blood-brain barrier permeable peptide comprising an amino acid sequence of SEQ ID NO: 3 is selected from the group consisting of SEQ ID NOS: 1 to 3.

### Claim 3 (depends on 1)

The blood-brain barrier permeable peptide according to claim 1, wherein the blood-brain barrier permeable peptide comprising an amino acid sequence of SEQ ID NO: 5 consists of an amino acid sequence of SEQ ID NO: 4 or SEQ ID NO: 5.

### Claim 4 (depends on 1)

A system for brain delivery of a target material comprising; the blood-brain barrier permeable peptide according to claim 1; and a target material bound to one terminal of the blood-brain barrier permeable peptide.

### Claim 5 (depends on 4)

The system for brain delivery of a target material according to claim 4, wherein the target material is selected from the group consisting of compounds, proteins, glycoproteins, peptides, nucleotides, nucleic acids, carbohydrates, lipids, glycolipids, nanoparticles, liposomes, drugs, lipid-based formulations, viruses, quantum dots and fluorochromes.

### Claim 6 (depends on 4)

The system for brain delivery of a target material according to claim 4, wherein the blood-brain barrier permeable peptide and the target material are linked by a covalent bond.

### Claim 7 (depends on 1)

A polynucleotide encoding the blood-brain barrier permeable peptide according to claim 1.

### Claim 8 (depends on 7)

A recombinant vector comprising the polynucleotide of claim 7.

### Claim 9 (depends on 4)

A pharmaceutical composition for treating or preventing brain or central nervous system diseases, comprising the system for brain delivery of a target material according to claim 4 as an active ingredient.

### Claim 10 (depends on 4)

A pharmaceutical composition for diagnosing brain or central nervous system diseases, comprising the system for brain delivery of a target material according to claim 4 as an active ingredient.
